BSX — Boston Scientific Income Statement
0.000.00%
Last trade - 00:00
- $122.68bn
- $130.58bn
- $14.24bn
- 93
- 13
- 98
- 76
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 10,735 | 9,913 | 11,888 | 12,682 | 14,240 |
Cost of Revenue | |||||
Gross Profit | 7,586 | 6,467 | 8,207 | 8,750 | 9,918 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 9,217 | 9,993 | 10,689 | 11,227 | 11,703 |
Operating Profit | 1,518 | -80 | 1,199 | 1,455 | 2,537 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 687 | -79 | 1,076 | 1,141 | 1,985 |
Provision for Income Taxes | |||||
Net Income After Taxes | 598 | -81 | 1,040 | 698 | 1,592 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 4,700 | -81 | 1,040 | 698 | 1,593 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 4,700 | -115 | 985 | 642 | 1,570 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.07 | 0.422 | 1.11 | 1.22 | 1.26 |